Last reviewed 2026-04-23 · How we verify

GA Depot

GA Depot is a long-acting gonadotropin-releasing hormone (GnRH) agonist depot formulation that suppresses luteinizing hormone and follicle-stimulating hormone secretion.

GA Depot is a long-acting gonadotropin-releasing hormone (GnRH) agonist depot formulation that suppresses luteinizing hormone and follicle-stimulating hormone secretion. Used for Advanced prostate cancer, Hormone-responsive breast cancer, Endometriosis.

At a glance

Mechanism of action

GA Depot works by providing sustained release of a GnRH agonist, which initially stimulates the pituitary gland but with continuous exposure leads to downregulation of GnRH receptors and suppression of gonadotropin secretion. This results in reduced testosterone or estrogen levels depending on the indication, making it useful for hormone-dependent conditions.

Approved indications

• Advanced prostate cancer
• Hormone-responsive breast cancer
• Endometriosis

Common side effects

• Hot flashes
• Injection site reactions
• Decreased libido
• Fatigue
• Headache

Key clinical trials

• Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS (PHASE2)
• Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS (PHASE1, PHASE2)
• A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• GA Depot CI brief — competitive landscape report
• GA Depot updates RSS · CI watch RSS
• Mapi Pharma Ltd. portfolio CI